Biotech Values

[DewDiligence]

In the handicapping of the Copaxone patent case on this board, posters have been treating obviousness and double patenting as a single argument for the sake of simplicity, although they are not exactly the same thing.

If you think Teva’s Orange Book patents are non-obvious, perhaps you should ask yourself whether they constitute a significant discovery relative to Teva’s older, expired patents. In mulling this question, consider the fact that no commercial product was developed as a direct consequence of the newer patents.